News

ivWatch Extends Its Global Reach Signing Three New Distribution Partners

Newport News, VA, ivWatch, LLC, an innovative IV safety company working to eliminate harm caused by infiltration and extravasation events, announced three new strategic distribution partnerships internationally. Bameco in Austria, Warba Medical Supplies in Kuwait, and Mustafa Sultan Science & Industry Co, LLC in Oman have each signed exclusive agreements to promote, sell, and support ivWatch’s continuous monitoring products in their markets. ivWatch’s novel technologies will complement and bolster their existing portfolios of intravenous products provided to hospitals and other health care facilities.

ivWatch solutions continue to be available in more countries throughout the globe and with the addition of Austria, Kuwait, and Oman, clinicians will now be able to improve their bedside decision-making with real-time IV infiltration data. Continuous IV site monitoring provides accurate and precise insights to detect infiltrations and extravasations at their earliest stages. ivWatch’s proprietary algorithm detects infiltrations promptly and notifies clinicians of adverse IV therapy events often hours before they are detectable by visual or tactile examination.1

“At ivWatch, we are on a steadfast mission to improve IV safety globally and we are extremely passionate about partnering with likeminded innovators who share that same relentless pursuit to advance patient safety,” said Chuck Egress, Vice President of Business Development and Emerging Markets at ivWatch. “IV infiltrations and extravasations are a major global patient safety concern, and these new partnerships provide increased access to advanced safety solutions to help end complications and improve patient outcomes in IV therapy.”

ivWatch has over 60 patents worldwide and received its first FDA clearance in 2015 for its IV site monitoring system that consists of an ivWatch Patient Monitor and a reusable optical biosensor that uses visible and near-infrared light to continuously measure changes in the optical properties of the tissue near an IV insertion site. In 2020, the company expanded its portfolio of sensor solutions and received FDA clearance for a single-use, miniaturized biosensor that is cleared for all patient age groups, sizes, and skin tones. Both sensors work seamlessly with the intuitive user interface on the Patient Monitor, which issues audible and visual “Check IV” alerts for the clinician to assess the IV site. ivWatch technology performs with high accuracy, intelligence, and low false alarm rates, which is critical to improving patient outcomes.

Read more here.

Recent News

07/19/2024

Capra Biosciences Lands $7.5 Million Project Agreement To Demonstrate Platform To Rapidly Scale Pharmaceutical Ingredient Manufacturing

Many ingredients that make up the pharmaceuticals Americans rely on are manufactured overseas. When supply chain issues or shortages occur, as witnessed during the COVID pandemic, it can negatively impact millions of Americans and affect national security. The White House issued an Executive Order in 2022 to stimulate U.S. biomanufacturing. Increasing American biomanufacturing, will provide

07/15/2024

Lupus Treatment with Omega3-Rich Krill Oil Improves Disease Activity

AMPEL BioSolutions, with collaborators Lupus Therapeutics and Aker Biomarine, revealed peer-reviewed results that supplementation with Omega3-rich Krill Oil improves disease activity of autoimmune Lupus patients. Omega3 lipids called polyunsaturated fatty acids (PUFAs) that are found in microscopic shrimp-like crustaceans called Krill from the waters around Antarctica are key to maintaining a low inflammatory state.  Some

07/15/2024

Inorganic Ventures acquires PURE Analytical Laboratories, Combining Unique Capabilities for Precision Manufacturing

Two privately held specialty chemical firms that provide high-purity materials and services for chemical applications, from renewable energy to food and beverages and consumer safety, are combining their capabilities to serve new and expanding precision markets. IV Labs Inc., the parent company of Inorganic Ventures, has acquired PURE Analytical Laboratories, one of the few companies that